Science & Technology
Developing Novel Ambroxol Analogs as Disease-Modifying Therapies for Alzheimer's Disease and Related Dementias
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AG097283-01
Award Ceiling
$497K
Award Floor
$497K
Close Date
Aug 31, 2026
169 days leftTotal Funding
$497K
Expected Awards
1
Posted Date
Sep 16, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R43AG097283-01
Description
SBIR Phase Phase I award: "Developing Novel Ambroxol Analogs as Disease-Modifying Therapies for Alzheimer's Disease and Related Dementias" awarded to Zywie LLC in Reno, Nevada. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $496,600. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.